Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experimental therapy in HCV infection].

Małgorzata Inglot1, Andrzej Gładysz, Weronika Rymer

  • 1Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odpornościowych AM we Wrocławiu.

Przeglad Epidemiologiczny
|September 30, 2005
PubMed
Summary

Hepatitis C treatment combines PEGInterferon and ribavirin but isn't always effective. Research explores new drugs and therapies, including targeting viral components and immune pathways, for better hepatitis C (HCV) treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MASLD in PLWH on ART: Predominance of Metabolic Risk Factors and Insights From Novel Biomarkers-A Cross-Sectional Study in Wrocław, Poland.

Journal of the International Association of Providers of AIDS Care·2026
Same author

Liver metabolic health and the components of metabolic syndrome in people living with HIV - do they differ from those in a 'healthy' population?

HIV research & clinical practice·2025
Same author

Mpox unveiled: Global epidemiology, treatment advances, and prevention strategies.

One health (Amsterdam, Netherlands)·2025
Same author

[Guidance for the occupational medicine service regarding the prevention of hepatitis C and HIV infection in Poland].

Medycyna pracy·2024
Same author

Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons.

Viruses·2023
Same author

HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV).

Cells·2023

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • The current gold standard for hepatitis C treatment, PEGInterferon and ribavirin combination therapy, has limitations in efficacy for all patients.
  • The development of robust hepatitis C virus (HCV) culture systems, such as replicons, is vital for advancing therapeutic strategies.
  • Identifying novel therapeutic targets within the HCV lifecycle and host immune pathways is crucial for improving treatment outcomes.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for hepatitis C.
  • To highlight the importance of developing new drugs and treatment regimens beyond standard therapy.
  • To explore the potential of targeting viral components and immunomodulatory pathways for novel anti-HCV therapies.

Main Methods:

Related Experiment Videos

  • Review of existing literature on hepatitis C treatment and drug development.
  • Analysis of advancements in HCV culture systems and their role in therapeutic intervention.
  • Exploration of different classes of antiviral agents, including polymerase and protease inhibitors, antisense nucleotides, ribozymes, and siRNA.
  • Consideration of immunomodulatory agents and novel interferon formulations for combination therapy.

    • Main Results:

    • Progress in HCV culture systems facilitates the development of drugs targeting viral NS5B polymerase and NS3/4A protease.
    • Antisense nucleotides, ribozymes, and siRNA represent promising avenues for HCV intervention.
    • Immunomodulatory pathways offer attractive targets for developing novel anti-HCV therapies.
    • New interferon formulations are being investigated for enhanced IFN-based therapy.

    Conclusions:

    • Combination therapy targeting multiple aspects of HCV infection is likely the future of successful hepatitis C treatment.
    • Further research into novel drugs and therapeutic regimens is necessary to overcome the limitations of current treatments.
    • Targeting both viral replication mechanisms and host immune responses holds significant promise for effective HCV management.